Article
Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome.
Science translational medicine - 1 Apr 2026
Li Zi-Juan, Zhao Mu-Ying, Wang Roujia, Liu Na, Hu Cheng-Long, Chang Binhe, Hu Fang, Li Xi-Ya, Xu Chun-Hui, Liu Ping, Chen Bing-Yi, Chen Shu-Bei, Wang Yong, Li Qi-Jing, Xue Bu-Sheng, Deng Chuhan, Chen Xinchi, Ren Yiyi, Jia-Cheng Jin, Yan Xiao, Zhang Yuanliang, Gale Robert Peter, Fu Jianfei, Zhang Qun-Ling, Wang Xiaoning, Huang Qiuhua, Liu Yan, Qiu Ju, Qin Jun, Ye Xueshi, Zhang Jin, Liang Yang, Chen Zhu, Chen Sai-Juan, He Peng-Cheng, Chang Chun-Kang, Sun Xiao-Jian, Wang Lan
Abstract excerpt
Patients with myelodysplastic syndrome (MDS) harboring SRSF2 (serine and arginine rich splicing factor 2) mutations exhibit poor prognosis and aberrant inflammatory activation, underscoring an urgent need for therapies. Here, we reveal that low messenger RNA expression of SETD2 (SET domain containing 2) in hematopoietic stem and progenitor cells (HSPCs) from patients with MDS carrying SRSF2P95 mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
